Literature DB >> 1508218

Expression of prolactin and its receptor in human lymphoid cells.

I Pellegrini1, J J Lebrun, S Ali, P A Kelly.   

Abstract

We have investigated whether human lymphoid cells are able to synthesize and secrete human PRL (hPRL) and to express PRL receptors. Metabolic labeling with [35S]methionine and immunoprecipitation of cell extracts from human mononuclear cells (MNC) and a human T lymphocyte cell line with an antiserum against hPRL revealed protein of M(r) 23,000, identical in size to pituitary hPRL. Dilution curves of lymphocyte immunoreactive hPRL were parallel to those obtained with pituitary hPRL in an immunoradiometric assay using two monoclonal antibodies against hPRL. Polymerase chain reaction experiments with primers located in the coding sequence of hPRL showed that the hPRL gene was expressed in MNC. Furthermore, cDNA cloning and sequence analysis indicated the presence of an extra 5' noncoding exon previously described for decidual hPRL. When MNCs were further separated into B cells, T cells, and monocytes, the expression of hPRL appeared to be mainly associated with the T lymphocyte fraction. The hPRL transcript was also detected in thymocytes and in a set of human lymphoid cell lines. Finally, polymerase chain reaction experiments revealed a ubiquitous distribution of PRL receptor gene expression in B cells, T cells, and monocytes. The presence of the receptor for PRL and production of PRL by T lymphocytes suggest a possible autocrine or paracrine effect of PRL in immune cell function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1508218     DOI: 10.1210/mend.6.7.1508218

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  41 in total

Review 1.  Mammary gland development in prolactin receptor knockout mice.

Authors:  C J Ormandy; N Binart; P A Kelly
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

2.  Prolactin-regulated pim-1 transcription: identification of critical promoter elements and Akt signaling.

Authors:  Nithya Krishnan; Huiqi Pan; Donna J Buckley; Arthur Buckley
Journal:  Endocrine       Date:  2003 Feb-Mar       Impact factor: 3.633

3.  Modulation of growth factor receptor function by isoform heterodimerization.

Authors:  W P Chang; C V Clevenger
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 4.  [Stress and the immune system].

Authors:  M Schedlowski; R E Schmidt
Journal:  Naturwissenschaften       Date:  1996-05

5.  Non-Hodgkin lymphoma with panhypopituitarism, hyperprolactinaemia and sixth nerve palsy.

Authors:  J A Shaw; F M Strachan; H A Sawers; J S Bevan
Journal:  J R Soc Med       Date:  1997-05       Impact factor: 5.344

6.  Role of prolactin in the in vitro development of interleukin-2-driven anti-tumoural lymphokine-activated killer cells.

Authors:  L Matera; G Bellone; J J Lebren; P A Kelly; E L Hooghe Peters; P F Di Celle; R Foa; M Contarini; G Avanzi; V Asnaghi
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

7.  Interleukin 2 activates STAT5 transcription factor (mammary gland factor) and specific gene expression in T lymphocytes.

Authors:  K C Gilmour; R Pine; N C Reich
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

8.  Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro.

Authors:  K Morkawa; F Oseko; S Morikawa
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

9.  Growth hormone activation of human monocytes for superoxide production but not tumor necrosis factor production, cell adherence, or action against Mycobacterium tuberculosis.

Authors:  J Warwick-Davies; D B Lowrie; P J Cole
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

10.  Prolactin modulates the naive B cell repertoire.

Authors:  Elena Peeva; Daniel Michael; James Cleary; Jeffrey Rice; Xian Chen; Betty Diamond
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.